Carvedilol extended release only — Competitive Intelligence Brief

Carvedilol extended release only (Carvedilol extended release only) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-selective beta-blocker. Area: Cardiovascular.

phase 2 Non-selective beta-blocker Beta-1 and beta-2 adrenergic receptors Cardiovascular Small molecule

Target snapshot

Carvedilol extended release only (Carvedilol extended release only) — GlaxoSmithKline. Carvedilol extended release is a beta-blocker that works by blocking the effects of the hormone epinephrine, also known as adrenaline, and by slowing the heart rate and reducing its workload.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carvedilol extended release only TARGET	Carvedilol extended release only	GlaxoSmithKline	phase 2	Non-selective beta-blocker	Beta-1 and beta-2 adrenergic receptors
Hydrocortisone/ Placebo and Propranolol	Hydrocortisone/ Placebo and Propranolol	University of Dundee	marketed	Glucocorticoid + Beta-blocker combination	Glucocorticoid receptor; Beta-1 and Beta-2 adrenergic receptors
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
betablocker titration	betablocker titration	Policlinico Casilino ASL RMB	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
amiodarone beta blocker sotalol	amiodarone beta blocker sotalol	Connolly, Stuart, M.D.	marketed	Beta-blocker with Class III antiarrhythmic activity	Beta-1 and beta-2 adrenergic receptors; potassium channels (IKr)
Timolol 0.5% Ophthalmic Solution	Timolol 0.5% Ophthalmic Solution	University of California, Davis	marketed	Beta-adrenergic antagonist	Beta-1 and beta-2 adrenergic receptors
Timolol 0.25% Ophthalmic Solution	Timolol 0.25% Ophthalmic Solution	Keith G. LeBlanc, Jr, MD	marketed	Beta-adrenergic antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-selective beta-blocker class)

1. CTI-1, LLC · 1 drug in this class
2. Generic (originally ICI/AstraZeneca) · 1 drug in this class
3. GlaxoSmithKline · 1 drug in this class